Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Derivative Claim - Update

18 Jun 2015 08:50

RNS Number : 5360Q
Elektron Technology PLC
18 June 2015
 



Elektron Technology plc 

("Elektron" or the "Company")

 

Derivative Claim - Update

 

In its 2015 Annual Report, on page 18, the Company provided an update in relation to the derivative litigation brought by a shareholder, Mr Bridge, who holds at the date of this announcement 1.83% of the Company's ordinary shares.

On 16 and 17 June 2015 Mr Bridge's application for permission to continue the intended claim against certain current directors, Keith Daley and John Wilson, and certain former directors, Noah Franklin and Simon Acland, (together "the Directors") was considered by the High Court in the Liverpool District Registry.

 

Mr Bridge represented himself at the hearing and both the Company and the Directors were represented by counsel instructed by their respective solicitors.

Permission has been refused by His Honour Judge Hodge QC with the effect that, subject to rights of appeal, the Derivative Claim will not continue.

In his judgment refusing permission, and addressing the Company's case, Judge Hodge QC was entirely satisfied that this was a clear case where the Court should refuse permission. The nature and strength of the claim, in light of the evidence of the Directors and the difficulty in establishing loss to the Company, were such that no reasonable director would support continuation of the litigation.His Lordship was satisfied that the Court should not compel the Company to continue the litigation when disinterested shareholders were not in support, and neither was the independent board.The Judge, having noted that a failure to properly and impartially consider the Company's evidence was a feature that had permeated all of Mr Bridge's submissions, accepted the Company's submission that the way Mr Bridge had conducted the litigation meant that it would not be appropriate to allow him to conduct litigation on the Company's behalf, or to require the Company to lend its name to the action.Mr Bridge has been ordered to pay all the costs of the Company and the Directors. He must make payments on account in the sums of £40,000 (in respect of the Company's costs) and £50,000 (in respect of the costs of the Directors) by close of business on 15 July 2015. Further, costs incurred after the wasted hearing on 1 October 2014 have been awarded on the indemnity basis as, by that time and with the benefit of legal representation, Mr Bridge should have seen the action as doomed for failure. His decision to continue it took the case "outside the commercial norm".

Mr Bridge did not apply for permission to appeal at the hearing, but he has 21 days from 17 June 2015 to do so. Any application for permission would need to be made to the Court of Appeal, setting out his grounds.Further updates will be provided in due course as appropriate.

 

 

For further information:

 

Elektron Technology www.elektron-technology.com

+44 (0) 1223 371 000

Andy Weatherstone - Chief Financial Officer

Martin Reeves - Company Secretary

finnCap

+44 (0)20 7220 0500

Ed Frisby/Scott Mathieson (Corporate Finance)

Malar Velaigam (Corporate Broking)

 

 

Notes to Editors

 

Elektron conceives, designs and markets innovative engineered products and services for businesses at its technology hub in Cambridge. It has a multi skilled team of engineers and product line specialists focused on the opportunities created by disruptive global trends in the following areas:

 

· Demand for ubiquitous power and data: Connectivity Solutions

· Internet of Things, cloud computing and mobile devices: enabling automation and management of a new wave of business processes: Checkit

· Growth in high precision manufacture: Nano-positioning

· Healthcare for the ageing population: Ophthalmology

· Connected customer experiences and service delivery: E-Commerce and E-Service

 

In addition, Elektron owns a portfolio of well-established products and brands which provide customer access and feedback.

 

Elektron Technology is headquartered in Cambridge and its shares are admitted to trading on the AIM market of the London Stock Exchange.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFSDRAITLIE
Date   Source Headline
8th Apr 20269:54 amRNSForm 8.5 (EPT/RI)
7th Apr 202611:44 amRNSForm 8.3 - Checkit plc
7th Apr 202610:30 amRNSForm 8.5 (EPT/RI)
1st Apr 202610:37 amRNSForm 8.5 (EPT/RI)
1st Apr 20269:38 amRNSForm 8.3 - Checkit PLC
1st Apr 20267:47 amRNSForm 8 (OPD) - Checkit plc
31st Mar 20262:50 pmEQSForm 8.3 - Checkit PLC
31st Mar 202611:29 amRNSForm 8.3 - Checkit plc
31st Mar 202611:12 amRNSHolding(s) in Company
31st Mar 202610:51 amRNSForm 8.5 (EPT/RI)
30th Mar 20261:58 pmRNSForm 8.3 - Checkit plc
30th Mar 202610:14 amRNSForm 8.5 (EPT/RI)
27th Mar 20263:39 pmRNSForm 8.3 Check it
27th Mar 20262:43 pmRNSForm 8.3 - Checkit PLC
27th Mar 202611:44 amRNSForm 8.3 - Checkit plc
27th Mar 202611:36 amEQSForm 8.3 - Checkit PLC
27th Mar 202610:40 amRNSForm 8.5 (EPT/RI)
27th Mar 202610:32 amRNSCheckit Plc - Form 8.3
26th Mar 202610:26 amRNSForm 8.3 - Checkit PLC
26th Mar 20267:45 amRNSDisclosure Table
26th Mar 20267:00 amRNSCommencement of Formal Sale Process
19th Feb 20267:00 amRNSFY26 Trading Update
21st Jan 202611:34 amRNSHolding(s) in Company
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
28th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20257:00 amRNSDirector/PDMR Shareholding
4th Nov 20257:00 amRNSDirector/PDMR Shareholding
30th Oct 20251:00 pmRNSDirector/PDMR Shareholding
28th Oct 20257:00 amRNSDirector/PDMR Shareholding
13th Oct 20252:52 pmRNSGrant of options and PDMR dealing
25th Sep 20257:00 amRNSDirector/PDMR Shareholding
26th Aug 20257:00 amRNSInterim Results
19th Jun 20252:36 pmRNSGrant of Options
5th Jun 20253:11 pmRNSResult of AGM
29th May 20257:00 amRNSPosting of Annual Report and Notice of AGM
22nd May 20257:00 amRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSFinal Results
17th Apr 20257:00 amRNSNotice of Results and Investor Presentation
8th Apr 20257:00 amRNSStrategic update
20th Mar 202512:31 pmRNSForm 8.5 (EPT/RI) - Amendment
20th Mar 202510:21 amRNSForm 8.5 (EPT/RI)
19th Mar 202512:02 pmRNSResult of General Meeting
18th Mar 20259:43 amRNSForm 8.5 (EPT/RI)
18th Mar 20259:23 amRNSForm 8.5 (EPT/NON-RI)
17th Mar 202512:01 pmRNSForm 8.5 (EPT/RI)
17th Mar 20258:56 amRNSForm 8.5 (EPT/NON-RI)
14th Mar 202511:57 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.